| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 62 |
| 1 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 57 |
| 2 | TACROLIMUS OINTMENT 0.1% | 57 |
| 3 | CYCLOPHOSPHAMIDE | 51 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 51 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 51 |
| 6 | RITUXIMAB | 50 |
| 7 | TOCILIZUMAB | 50 |
| 8 | AXICABTAGENE CILOLEUCEL | 46 |
| 9 | METHYLPREDNISOLONE | 46 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | THROMBIN TOPICAL RECOMBINANT | 1 | 0.0147 |
| 1 | AXICABTAGENE CILOLEUCEL | 46 | 0.0045 |
| 2 | SODIUM POLYSTYRENE SULFONATE | 7 | 0.0044 |
| 3 | CLOFARABINE | 8 | 0.0035 |
| 4 | SILTUXIMAB | 2 | 0.0031 |
| 5 | PRUCALOPRIDE SUCCINATE | 1 | 0.0029 |
| 6 | L-GLUTAMINE | 1 | 0.0028 |
| 7 | BREXUCABTAGENE AUTOLEUCEL | 5 | 0.0023 |
| 8 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 9 | MINERAL OIL AND WHITE PETROLATUM | 1 | 0.0019 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD19-directed Chimeric Antigen Receptor [EPC] | 46 | 0.0045 |
| 1 | Interleukin-6 Antagonist [EPC] | 2 | 0.0031 |
| 2 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 3 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 4 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 5 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 6 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 16 | 0.0012 |
| 7 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 96 | 0.0010 |
| 8 | Guanylate Cyclase-C Agonist [EPC] | 2 | 0.0010 |
| 9 | Aldehyde Dehydrogenase Inhibitor [EPC] | 1 | 0.0009 |